Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptomatic case 88% primary Improvement Relative Risk c19ivm.org Mondal et al. Ivermectin for COVID-19 Prophylaxis Favors ivermectin Favors control
Prevalence of COVID-19 Infection and Identification of Risk Factors among Asymptomatic Healthcare Workers: A Serosurvey Involving Multiple Hospitals in West Bengal
Mondal et al., Journal of the Indian Medical Association, 119:5
Mondal et al., Prevalence of COVID-19 Infection and Identification of Risk Factors among Asymptomatic Healthcare Workers: A.., Journal of the Indian Medical Association, 119:5
May 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,470 healthcare workers in India, showing significantly lower risk of symptomatic COVID-19 with ivermectin prophylaxis.
risk of symptomatic case, 87.9% lower, RR 0.12, p = 0.006, treatment 128, control 1,342, adjusted per study, odds ratio converted to relative risk, control prevalence approximated with overall prevalence, multivariable, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mondal et al., 31 May 2021, retrospective, India, peer-reviewed, 11 authors, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Vol 119, No 5, May 2021 21 Journal of the Indian Medical Association Original Article Prevalence of COVID-19 Infection and Identification of Risk Factors among Asymptomatic Healthcare Workers : A Serosurvey Involving Multiple Hospitals in West Bengal Sunetra Mondal1, Arijit Singha2, Debaditya Das3, Subhasis Neogi2, Piyas Gargari2, Moxit Shah2, Durairaj Arjunan2, Pradip Mukhopadhyay4, Sujoy Ghosh5, Jyothi Chowdhury6, Subhankar Chowdhury7 Background : The declining trend of COVID-19 infection in India has made healthcare personnel (HCP) and general public lenient about personal-protective-measures. Serosurveys to estimate the prevalence of SARS-CoV2 IgG antibodies, particularly in high-risk-zones like hospitals can give the real scenario and risk-factors can help prioritise the target population for urgent, effective vacccination. Methods : 1470 consecutive HCP from 4 tertiary-care-hospitals in Kolkata filled a questionnaire and were tested for serum SARS-CoV2-IgG by Enzyme-linked Immunosorbent Assay (ELISA). The prevalence of SARS-CoV2-IgG among asymptomatic HCPs was studied and the work environment, clinical comorbidities, personal habits and protective measures and pharmacologic prophylaxes were compared between those with and without SARS-CoV2IgG. Parameters of asymptomatic seroconverters were also compared to those with personal history of COVID-19Infection. Logistic regression was done to identify independent risk-factors. Results : Prevalence of asymptomatic seroconversion was 15.8%. Asymptomatic seroconverters (n=208) were mostly working in mixed hospitals (having both COVID-19 and non-COVID-19 wards, 57.7%), were non-doctors by profession (nurses-25.1%, others–51.4%). Among asymptomatic HCP, indepedendent positive risk factors for SARSCoV2 IgG-positivity were Diabetes Mellitus (DM) and multiple comorbidities (pboth<0.001) and prophylactic use of Hydroxychloroquine and Famotidine (pboth< 0.03). However, for symptomatic COVID-19 infection, working in COVID19 dedicated hospitals, and personal h/o COPD were positive risk-factors and Ivermectin prophylaxis a negative riskfactor (pall< 0.03). Conclusion:In our study conducted in the immediate pre-immunisation period, rate of asymptomatic seroconversion among HCPs is too low to presume herd immunity. Those working in mixed hospitals and DM, multiple comorbidities are at particularly high risk. [J Indian Med Assoc 2021; 119(5): 21-7] Key words : COVID-19, SARS-CoV2 IgG, ELISA, Seroprevalence, Healthcare personnel. M ore than a hundred million people worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) over the past fourteen months. With the vaccination campaign targeting healthcare workers and the sudden decline in the daily number of cases in the country, the Department of Endocrinology and Metabolism, IPGME&R, Kolkata 700020 1 MBBS, MD (Medicine), DM (Endocrinology), Postdoctoral Senior Resident and Corresponding Author 2 MBBS, MD (Medicine), Postdoctoral Trainee 3 MBBS, DNB (Pediatrics), Postdoctoral Trainee 4 MBBS, MD (Medicine), DM (Endocrinology), Professor 5 MBBS, MD (Medicine), DM (Endocrinology), FRCP, FACE, Speciality Certificate in Endocrinology, FICP, Professor 6 MBBS, DNB (Pathology), Consultant Pathologist, Scientific Clinical Research Laboratory, Kolkata 700013 7 MBBS, DTM&H, MD (Medicine), DM (Endocrinology), MRCP, Professor and Head Received on : 08/03/2021 Accepted on : 23/03/2021 Editor's Comment : „ Among 1470..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit